Immunotherapy is one of the most promising avenues of research in the battle against cancer. As initial checkpoint inhibitors come to market, the immuno-oncology development landscape is exploding. Now, the pressure is on to apply insights from existing studies to assure future trials are quick and efficient, yield high-quality data, and ensure patient safety.
In this webinar, we’ll share lessons learned for your immuno-oncology program through examining the challenges that come with the new complexities of immuno-oncology studies:
By attending this webinar you will:
Eric Groves, MD, PhD
Vice President, Advisory Services
Board certified in oncology and internal medicine, Dr. Groves has more than 20 years’ experience in drug development as corporate officer/senior manager, clinician and researcher. Prior to joining Quintiles in August of 2007, Dr. Groves was at Ligand Pharmaceuticals Inc., starting in August 1999 as Vice President, Project Management and corporate officer. From 1994 until joining Ligand, Dr. Groves held a number of positions at Sanofi Pharmaceuticals, most recently as Vice President, Project Direction, where he was responsible for the worldwide strategy of and project direction for late-stage Sanofi oncology projects. From May 1991 through October 1994, Dr. Groves served as Senior Project Director for the research division of Sterling Winthrop Corporation, and served as acting Vice President, Discovery and Clinical Research, Immunoconjugate Division. He was Director of Clinical Research and Development at CETUS Corporation from 1989 through 1991.
Matthew Bentley, PhD
Clinical Project Manager, Oncology
Matthew Bentley is a Clinical Project Manager in oncology therapeutics at Quintiles. Since 2013, he has been involved with a range of phase I to III oncology studies including immuno-oncology studies in non-small cell lung cancer, melanoma, and colorectal cancer. In addition to managing clinical studies, Dr. Bentley helped develop Quintiles’ immuno-oncology training program designed to educate clinical monitors and project managers in key aspects of the immuno-oncology landscape, with topics such as Mechanisms of Action, Immune-related Adverse Events and Safety Considerations, and irRC and Modified RECIST. Prior to Quintiles, Dr. Bentley was a scientist in the discovery group at Trius Therapeutics, an early-stage biotech focused on the discovery and development of novel antibiotics. He holds a Ph.D. in Biochemistry from University of Pennsylvania and completed a Postdoctoral Research Fellowship in protein engineering at Genentech.
Kathleen Gray, PhD
As scientific advisor for Q2 Solutions, Kathleen Gray, Ph.D. provides therapeutic and protocol-specific guidance for biomarker testing and trial design for oncology clinical studies.
Dr. Gray joined Quintiles Laboratories in 2011, prior to the formation of Q2 Solutions through a joint venture between Quintiles and Quest Diagnostics. She specializes in oncology biomarkers with a focus on the incorporation of novel biomarker assays into clinical oncology protocols, including the development and implementation of companion diagnostic strategies. Previously, Dr. Gray studied the host immune response to chronic viral infection and the molecular mechanisms of pathogen-induced cellular transformation. Dr. Gray holds a B.S. degree in Biology from University of Michigan in Ann Arbor, Mich. and a Ph.D. in Immunology and Molecular Pathogenesis from Emory University in Atlanta, Ga.